Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:21:53 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:NTRA - NATERA INC - http://www.natera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NTRA - Q9.984.70·85.619.985.28-2.00-2.32,526.1213,12523,10387.00  87.195  83.1398.82  36.9016:53:58Apr 1115 min RT 2¢

Recent Trades - Last 10 of 23103
Time ETExPriceChangeVolume
16:53:58Q85.28-2.007,984
16:50:57Q85.28-2.0048,984
16:04:44Q85.28-2.001,554
16:04:38Q85.28-2.009,788
16:04:34Q85.28-2.00129
16:04:33Q85.28-2.00100
16:04:24Q85.28-2.00242,205
16:04:21Q85.28-2.0091
16:04:20Q85.28-2.00134
16:04:02Q85.28-2.00665

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-11 08:00U:NTRANews ReleaseNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
2024-04-08 08:00U:NTRANews ReleaseNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera(TM) Heart dd-cfDNA Test for Heart Transplant Recipients
2024-04-05 07:00U:NTRANews ReleaseNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
2024-04-01 08:00U:NTRANews ReleaseNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
2024-03-18 07:00U:NTRANews ReleaseNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera(TM) in Stage II Colorectal Cancer
2024-03-14 08:00U:NTRANews ReleaseNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
2024-03-12 08:00U:NTRANews ReleaseNatera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
2024-03-07 08:00U:NTRANews ReleaseNatera Announces Commercial Coverage for Prospera(TM) Kidney and Prospera Heart(TM) from a Top BCBS Plan
2024-02-29 08:00U:NTRANews ReleaseNatera to Participate in March Investor Conferences
2024-02-28 16:05U:NTRANews ReleaseNatera Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 08:00U:NTRANews ReleaseNatera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
2024-02-26 07:00U:NTRANews ReleaseMedicare Extends Coverage of Natera's Signatera(TM) MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
2024-02-20 08:00U:NTRANews ReleaseNatera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
2024-02-05 08:00U:NTRANews ReleaseNew Study Validates Signatera ¢ „ ¢ in Endometrial Cancer
2024-01-30 09:15U:NTRANews ReleaseMultiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
2024-01-30 07:00U:NTRANews ReleaseNew Publication Demonstrates Signatera ¢ € ™s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
2024-01-29 07:00U:NTRANews ReleaseJury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
2024-01-25 07:00U:NTRANews ReleaseNature Medicine Publishes Two Studies Highlighting Signatera ¢ € ™s Clinical Utility in Patients with Gastrointestinal Malignancies
2024-01-22 07:00U:NTRANews ReleaseNatera Acquires Reproductive Health Assets from Invitae
2024-01-22 07:00U:NTRANews ReleaseInvitae Completes Sale of Reproductive Health Assets to Natera